Prospective, Multi-Center, Observational Program to Assess RSV Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis in Routine Clinical Setting in the Russian Federation

Trial Profile

Prospective, Multi-Center, Observational Program to Assess RSV Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis in Routine Clinical Setting in the Russian Federation

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Jul 2016

At a glance

  • Drugs Palivizumab (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Therapeutic Use
  • Acronyms SUNRISE
  • Sponsors AbbVie
  • Most Recent Events

    • 05 Jun 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record.
    • 18 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 10 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top